Miragen Therapeutics has named Arthur Levin as its new executive vice president of research and development.
In this role, Levin will be responsible for advancing the company's drug candidates into clinical development and for leading drug-discovery research efforts, according to Miragen.
Levin previously served as chief development officer and president of Santaris Pharma's US operations. Before that, he was senior vice president of development at Isis Pharmaceuticals.
Alnylam Pharmaceuticals has appointed Dennis Ausiello to its board of directors and scientific advisory board.
Ausiello is currently a professor of clinical medicine at Harvard Medical School and chief of medicine at Massachusetts General Hospital.